Ambroxol and its anti-viral activity. A commentary to human and animal studies Commentary
Article Sidebar
Published:
Mar 31, 2019
Keywords:
ambroxol, rhinoviruses, influenza
Main Article Content
Abstract
Mucolytic and mucokinetic agents are widely utilized in everyday clinical practice. They are prescribed mostly in upper and lower airway infections, as well in chronic bronchitis and chronic obstructive pulmonary disease treatment. Are they all identical? No. Some of them have extra properties, and could deliver some additional benefits. In this short review we focused on ambroxol. Ambroxol delivers well documented antiviral activity, decreasing RV and influenza proliferation rate. Therefore, ambroxol might decrease the length of rhinoviral and influenza airway infections, as well could be useful in chronic obstructive pulmonary disease exacerbations prevention.
Article Details
How to Cite
Pawliczak , R. (2019). Ambroxol and its anti-viral activity. A commentary to human and animal studies. Medycyna Faktow (J EBM), 12(1(42), 28-31. https://doi.org/10.24292/01.MF.0119.4
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. O’Grady K.F., Grimwood K., Sloots T.P. et al.: Prevalence, codetection and seasonal distribution of upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a symptom. Clin. Microbiol. Infect. 2016; 22(6): 527-534.
2. Papi A., Bellettato C.M., Braccioni F. et al.: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173(10): 1114-1121.
3. Seemungal T.A., Wedzicha J.A.: Viral infections in obstructive airway diseases. Curr. Opin. Pulm. Med. 2003; 9(2): 111-116.
4. Renom F., Yáñez A., Garau M. et al.: Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir. Med. 2010; 104(6): 840-848.
5. Yamaya M., Nishimura H., Nadine L.K. et al.: Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch. Pharm. Res. 2014; 37(4): 520-529.
6. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
7. Malerba M., Ragnoli B.: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008; 4(8): 111-1129.
8. Nowak D.: [Antioxidative features of ambroxol – usefulness in COPD]. Pneumonol. Alergol. Pol. 2001; 69(9-10): 590-593.
9. Beeh K.M., Beier J., Esperester A., Paul L.D.: Antiinflammatory properties of ambroxol. Eur. J. Med. Res. 2008; 13(12): 557-562.
10. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin. Drug Saf. 2018; 17(12): 1211-1224.
2. Papi A., Bellettato C.M., Braccioni F. et al.: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173(10): 1114-1121.
3. Seemungal T.A., Wedzicha J.A.: Viral infections in obstructive airway diseases. Curr. Opin. Pulm. Med. 2003; 9(2): 111-116.
4. Renom F., Yáñez A., Garau M. et al.: Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir. Med. 2010; 104(6): 840-848.
5. Yamaya M., Nishimura H., Nadine L.K. et al.: Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch. Pharm. Res. 2014; 37(4): 520-529.
6. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
7. Malerba M., Ragnoli B.: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008; 4(8): 111-1129.
8. Nowak D.: [Antioxidative features of ambroxol – usefulness in COPD]. Pneumonol. Alergol. Pol. 2001; 69(9-10): 590-593.
9. Beeh K.M., Beier J., Esperester A., Paul L.D.: Antiinflammatory properties of ambroxol. Eur. J. Med. Res. 2008; 13(12): 557-562.
10. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin. Drug Saf. 2018; 17(12): 1211-1224.